Ticalopride

DB06422ExperimentalSmall molecule

Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastroparesis.

Mechanism: Ticalopride is an isomer of the active metabolite of cisapride. Cisapride acts through the stimulation of the serotonin 5-HT4 receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.
Curator reviewed
Primary indication: Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastroparesis.Curator reviewed
Formula / weight: C₁₄H₂₀ClN₃O₃ · 313.78 g/mol (avg)
Also known as: Norcisapride

Resolves to

Compound

Structure

InChIKeyOMLDMGPCWMBPAN-YPMHNXCESA-NSMILESCO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC

Targets

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Drug interactionStructured to mechanism, not free text

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ticalopride, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.